Table 2.
Baseline characteristics in the subgroups of patients who did and did not develop DSAs
| BENEFIT | BENEFIT‐EXT | |||
|---|---|---|---|---|
| De novo DSA‐positive (n = 37) | De novo DSA‐negative (n = 623) | De novo DSA‐positive (n = 29) | De novo DSA‐negative (n = 507) | |
| Mean age, y (SD) | 35.4 (13.3) | 43.7 (14.0) | 53.7 (11.7) | 56.3 (12.5) |
| Male, n (%) | 26 (70.3) | 432 (69.3) | 15 (51.7) | 343 (67.7) |
| Region | ||||
| North America | 22 (59.5) | 269 (43.2) | 6 (20.7) | 130 (25.6) |
| South America | 1 (2.7) | 101 (16.2) | 12 (41.4) | 129 (25.4) |
| Europe | 9 (24.3) | 155 (24.9) | 11 (37.9) | 245 (48.3) |
| Rest of world | 5 (13.5) | 98 (15.7) | 0 (0) | 3 (0.6) |
| Categorized PRA, n (%) | ||||
| <20% | 36 (97.3) | 538 (86.4) | 26 (89.7) | 477 (94.1) |
| ≥20% | 1 (2.7) | 70 (11.2) | 0 (0) | 7 (1.4) |
| Missing | 0 (0) | 15 (2.4) | 3 (10.3) | 23 (4.5) |
| Reported cause of ESRD, n (%) | ||||
| Glomerular disease | 15 (40.5) | 161 (25.8) | 6 (20.7) | 113 (22.3) |
| Diabetes | 3 (8.1) | 75 (12.0) | 4 (13.8) | 76 (15.0) |
| Polycystic kidneys | 2 (5.4) | 89 (14.3) | 4 (13.8) | 91 (17.9) |
| Hypertensive nephrosclerosis | 3 (8.1) | 59 (9.5) | 4 (13.8) | 90 (17.8) |
| Renovascular and other vascular diseases | 0 (0.0) | 12 (1.9) | 0 (0) | 10 (2.0) |
| Congenital, rare familial, and metabolic | 0 (0) | 23 (3.7) | 0 (0) | 6 (1.2) |
| Disorders | ||||
| Tubular and interstitial diseases | 1 (2.7) | 33 (5.3) | 3 (10.3) | 26 (5.1) |
| Re‐transplant/graft failure | 0 (0) | 7 (1.1) | 0 (0) | 0 (0) |
| Other | 13 (35.1) | 164 (26.3) | 8 (27.6) | 95 (18.7) |
| HLA mismatches, n (%) | ||||
| 4 | 7 (18.9) | 127 (20.4) | 8 (27.6) | 132 (26.0) |
| 5 | 7 (18.9) | 70 (11.2) | 5 (17.2) | 100 (19.7) |
| 6 | 6 (16.2) | 53 (8.5) | 4 (13.8) | 34 (6.7) |
| Missing | 0 (0) | 17 (2.7) | 1 (3.4) | 0 (0) |
DSA, donor‐specific antibody; ESRD, end‐stage renal disease; LI, less intense; MI, more intense; PRA, panel reactive antibody; SD, standard deviation.